Some patients report noticeable cosmetic changes after 2 to 4 months of consistent use
Injection site reactions, including bruising, are documented adverse effects in semaglutide clinical trials, though bruising is not separately reported in FDA labeling
Verywell Health Key takeaways ADA 2025 supports CGM broadly, with expanded consideration for adults with type 2 diabetes beyond insulin
Erhhte Infektanflligkeit und entsprechende Infektionskrankheiten von Influenza bis Herpes knnen ebenfalls ein Hinweis auf einen schlechten Glutathionstatus sein
doi:10.1055/s-0040-1714091 [12] Allam MM, El-Zawawy HT, Barakat SS, Ahmed SM, Saleh RNM
QUALITY & SAFETY: Produced in a cGMP (Good Manufacturing Practices) facility and aggressively tested for safety